News & events
First US customer signs commercial contract
Q-linea resolves on the terms for a rights issue of approximately SEK 225 million
Q-linea AB (publ) (”Q-linea” or the “Company”) announces that the board of directors today has resolved on the terms...
Read more >
BULLETIN FROM Extraordinary GENERAL MEETING IN Q-LINEA AB (PUBL)
The extraordinary general meeting of Q-linea AB (publ) (the “Company”), org.nr. 556729-0217, was held on 6 December 2024 in...
Read more >
NOTICE OF EXTRAORDINARY GENERAL MEETING IN Q-LINEA AB (PUBL)
The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to an extraordinary general meeting...
Read more >
Q-linea resolves to carry out a rights issue of approximately SEK 225 million and enters into an agreement for a bridge loan facility of approximately SEK 40 million
Q-linea AB (publ) (”Q-linea” or the “Company”) announces that the board of directors today has resolved to carry out...
Read more >
ASTar® evaluation begins at a US National Cancer Institute-designated cancer center
Q-linea AB (publ) (OMX: QLINEA) today announces the initiation of the first clinical evaluation of ASTar® at a National...
Read more >
Load more